RA Capital Management 13F holdings, Q4 2008
Holdings as of December 31, 2008 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 8 US equity positions worth $224.4m in its Q4 2008 13F filing. The largest position was SEQUENOM INC at 66.8% of the reported book, followed by PHARMASSET INC and ARDEA BIOSCIENCES INC. Against the Q3 2008 filing, it opened 2 new positions, added to 3 and reduced 3 among the top 8 holdings.
What did RA Capital Management own in Q4 2008? Top 8 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2008 |
|---|---|---|---|---|---|---|---|
| 1 | SEQUENOM INC | 66.8% | $150.0m | 7,558,080 | -6% | reduced | |
| 2 | PHARMASSET INC | 8.3% | $18.6m | 1,421,575 | 82% | added | |
| 3 | ARDEA BIOSCIENCES INC | 8.0% | $17.9m | 1,494,762 | 224% | added | |
| 4 | AMAG AMAG PHARMACEUTICALS INC | 5.8% | $13.1m | 364,500 | 68% | added | |
| 5 | VRTX VERTEX PHARMACEUTICALS INC | Healthcare | 4.6% | $10.4m | 342,044 | -23% | reduced |
| 6 | AUXILIUM PHARMACEUTICALS INC | 4.2% | $9.4m | 329,713 | – | new | |
| 7 | CRIS CURIS INC | 1.6% | $3.6m | 4,790,959 | -15% | reduced | |
| 8 | GILD GILEAD SCIENCES INC | Healthcare | 0.7% | $1.5m | 30,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.